Drug Approval | December 12, 2025
Bristol Myers Squibb scores FDA priority review for Opdivo in advanced hodgkin lymphoma
The FDA aims to make a decision by April 8, 2026
The FDA aims to make a decision by April 8, 2026
The U.S. oncology market is projected to soar from $81 billion in 2025 to $212 billion by 2034
This is the first approval of a prescription transdermal dosage Form in the European markets from this facility
The company has unveiled the results of pirtobrutinib from its BRUIN CLL-313 study
India has deep strengths in reverse engineering and API development, while Russia has strong capabilities in certain vaccines, biologicals, and niche therapeutic segments. Collaboration can significantly shorten R&D timelines
The agreement pairs Croda’s global footprint and “smart science” approach with Amino’s precision manufacturing capabilities
The new site will produce next-generation synthetic medicine active pharmaceutical ingredients
The new site marks the company’s first operation in the region
This strategic investment aims to bolster the company's position as a global leader in Vitamin D3 manufacturing
Formycon AG will develop, register, manufacture and supply the product, while Zydus Lifesciences Global FZE, United Arab Emirates will be responsible for the commercialization of FYB206 in the defined territories
Subscribe To Our Newsletter & Stay Updated
